Total : %
04.22.18 12:31:30PM
Biotech Upcoming data
| Ticker | Phase | Drug | Notes |
|---|---|---|---|
| ALDX | 2 and 3 | Reproxalap Ocular | Phase 3 Allergic Conjunctivitis , P2b Dry Eye Disease, P3 Noninfectious Anterior Uveitis and P3 sjogren-Larsson Syndrome. All expected second half 2018 |
| ALNY | 3 | ENVISION | interim analysis mid-2018 |
| AMRN | 3 | REDUCE-IT | Topline results expected to be available before the end of Q3 2018 |
| AQYP | 3 | AQX-1125 | LEADERSHIP data |
| ARGS | 2 | AGS-004 | interim data due 2h 2018 |
| ATNX | 3 | Oraxol KX-ORAX-001 | second inerim analysis in 3Q 2018 |
| BYSI | 3 | Piabulin | Interim P3 mid-2018 |
| CANF | 2 | Namodenoson | Namodenoson in the treatment of heaptacellular carcinoma (HCC) expected later in 2018 |
| EIGR | 2 | Exendin 9-39 IN PBH | Exedin 9-39 phase 2 PREVENT study, and Ubenimex in Lymphedema; phase 2 ULTRA study completion. |
| ESPR | 3 | Bempedoic Acid | Global pivotal P3 study 2 52 weeks LDL-C |
| FLKS | 2b | COMMEND trial FLXS-787 | Topline 3q 2018 |
| FOMX | 3 | FMX101 | Top-line results are epected in the 3Q 2018 |
| MRNS | 2 | Intravenous (IV) ganaxolone | Report top-line P2 Magnolia study in women with PPD |
| OBSV | 2B | OBE2109 | due mid 2018 |
| OCUL | 3 | OTX-TP | Expects topline efficacy data 2h 2018 |
| ONCS | 2b | PISCES/KEYNOTE-695 | Dosing of first patient on Dec 14, 2017. data in 2018. (No specific quarter given) |
| OVID | 2 | OV101- STARS | Enrollment i n STARS trial to adolescent Angelman syndrome. Trial to be available 2H 2018 |
| RHDL | 3 | RHB-104 | Topline data |
| TNXP | 3 | HONOR study of Tonmya | Interim Analysis 3Q 2018;Topline results expected in 4Q 2018 |
| URGN | 3 | OLYMPUS | topline data |
| XLRN | 3 | MEDALIST and BELIEVE | Luspatercept are expected mid-2018 |
| Ticker | Phase | Drug | Notes |
|---|---|---|---|
| ACRS | 2 | AT-50002 Topical | Top-line data 1H 2018 |
| ALXN | 3 | PREVENT and ALXN210 | Data mid-2018. Eculizumab- Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) |
| AVEO | 3 | TIVO-3 | Topline data |
| AXSM | 3 | STRIDE-1 | trial of AXS-05 IN TRD, top-line data 1H 2018 |
| CLDX | 2b | METRIC | Topline data likely Q2 2018 |
| CLSD | 2 | TYBEE | Patients follow-up six months data |
| EDGE | 3 | EG-1962 | Interim-topline data |
| ESPR | 3 | ASCVD and/or HeFH Statin add on | Global pivotal P3 study 1, 52 weeks long term safety. |
| FOMX | 3 | FMX103 | Topline data mid 2018 |
| GEMP | 2B | INDIGO-1 | Top-line data |
| IDRA | 2 | IMO-8400 | Data 1H 2018 |
| INCY | 3 | ECHO-301 | Initial results of the ECHO-301 trial of epacadostat in melanoma and REACH 1 trial of ruxolittinib in acute GVHD |
| IONS | P1/2a | IONIS-SOD1 ALS | Topline Data Mid Q2 |
| JNCE | 1/2 | ICONIC | Preliminary Efficacy data in the first half of 2018 |
| KPTI | 2b | STORM | April data |
| MNLO | 2 | ATOMIK | atopic dermatitis data expected April 2018 |
| NBRV | 3 | LEAP 2 | Data are expecting in Spring 2018 |
| PRTA | IIb | NEOD1 | Top-line data |
| SBBP | 3 | RECORLEV | Top-line results on track with SONICS |
| SELB | 2 | SEL-212 | Symtomatic Gout Patients. Updated Clinical data at PANLAR Congress on Tuesday, April 10, 2018 |
| TGTX | 2b | UNITY-CLC | Top-line ORR data |
| VICL | 2 | HSV-2 | Therapeutic Vaccine |
| VTVT | 3 | STEADFAST | STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 |
| XLRN | 3 | MEDALIST and BELIEVE | Data mid 2018 |
| ZGNX | 3 | ZX008 | Second pivotal trial Phase 3 Dravet Synddrome program, Study 1504. |
| Ticker | Phase | Drug | Notes |
|---|---|---|---|
| ACOR | 3 | Tozadenant | Phase 3 data |
| AIMT | 3 | PALISADE | "Anticipate sharing topline in first quarter 2018" |
| ANAB | 2 | ANB020 | Phase 2 data readout in adult severe peanut allergy. |
| ANTH | 3 | Sollpura-RESULT | data due end of Q1 |
| ARGX | 2 | ARGX-113 | Myasthenia gravis data |
| AXON | 2 | Intepirdine and Nelotanserin | January data: HEADWAY in patients with dementia with Levy bodies (DLB). subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Nelotanserin (LBD). |
| AXSM | 3 | CREATE-1 | trial of AXS-02 in CRPS, interim efficacy analysis |
| BHVN | 3 | RIMEGEPANT | Top-line results |
| BLPH | 3 | INO pulse for PAH indication | Topline line data |
| BOLD | 1/2 | AT132 | Phase 1/2 data readout of AT132 XLMTM |
| CDTX | 2 | STRIVE | CD101 IV |
| Cidara Therapeutics Inc (CDTX) | 2 | STRIVE | completing enrollment of the 90-patietn. P2 Rezafungin |
| CLSD | 3 | PEACHTREE | Macular Edema Associated with Non-infectious Uveitis, top line data. |
| CPRX | 2 | CMS-001 | Expect top-line results from CMS-001 in first half 2018 |
| DERM | 3 | CLAREOS 1 and CLAREOS 2 | October 5, 2017 completes patient enrollment in Two Phase 3 pivotal trials of Olumacostat Glasaretil for the treament of Acne Vulgaris. Topline. |
| EARS | 3 | KEYZILEN | P3 TACTT3 topline data |
| EIGR | 2 | LIBERTY | Ubenimex in PAH |
| EYEG | 3 | EGP-437 | Topline data |
| FGEN | 2 | FG-3019 | Pancreatic caner study results |
| FLKS | 2 | FLX-787 Multiples Sclerosis | Readout data end of Q1 |
| GEMP | 2b | INDIGO-1 | top-line data |
| GLMD | 2b | ARREST | Phase IIB data late Q1 or early Q2 2018. |
| GTHX | 2a | trilaciclib | trilaciclib first-in-line small cell lung cancer. Data in March |
| IDRA | 2 | IMO-2125 | Clinical trial of 8mg intratumoral IMO-2125 in combination with ipilimumab in anti-PD1 reffractory melanoma. ORR data |
| MNOV | 2 | mn-166 | Completion enrollment news on Sept 19,2017. Final data Q1 |
| MRNS | 2 | CDKL5 | on-going in the Magnolia Study, with data expected in early 2018 |
| OVID | 2 | STARS | Sometimes 2018 |
| PTGX | 2b | PTG-300 | interim analysis early 2018 |
| REGN | 3 | Praluent ODYSSEY OUTCOMES | Cardiovascular events. |
| TCON | 2 | TRAXAR trial of TRC105 | Top-line data from the randomized P2 |
| TRPX | IIa | THX-110 | Tourette syndrome. Top-line anticipated in first half 2018 |
| TTPH | 3 | IGNITE3 | Additional data |
| VBLT | 3 | VB-111 | top-line results |
| VICL | 3 | ASP0013 | The multinational phase 3 registration trial in HCT recipients completed enrollment in Sept 2016 with a total 515 subjects. |
| VRTX | 2 | VX-445 and VX-659 triple combinations in CF patietns | data 1H18 |
| VTGN | 2 | AV-101 | P2 monotherapy study completion expected early 2018 |
| VTVT | 3 | STEADFAST | STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018 |
| Ticker | Phase | Drug | Notes |
|---|---|---|---|
| ADRO | 2 | CRS-207 in combination with pembrolizumab | Report early observations from the ongoing phase 2 mesothelioma study |
| AGLE | 1 | AEB1102 | Potential data end of year. |
| ANAB | 2a | ANB020 | Multiple Top-Line Clinical data readouts expected in second half of 2017 |
| ARDX | 3 | T3MPO-2 | Results of Tenapanor for IIBS-C on track early Q4 |
| AVXL | 2a | ANAVEX 2-73 | PK/PD data |
| CALA | 2 | CB-839 | In July 2017, Calithera initiated a phase 2 trial of CB-839 with pcitaxel in triple negative breast cancer patietns. |
| CLDX | 2 | Glembatumumab Vedotin | The company anticipated in fall of 2017 |
| CNCE | 2b | CTP-543 | End of year data |
| CPRX | 3 | Firdapse® | Top-line Results expected in early December. Completes enrollment in second phase 3 trial on Oct 31,2017 |
| CYTK | 3 | VITALITY-ALS | Trial of Tirasemtiv |
| DBVT | 3 | PEPITES | to report topline results from PEPITES in October 2017 |
| EARS | 3 | AM-111 HEALOS | The trial enrolled 256 patients with severe to profound idiopathic sudden sensorineural hearing loss. |
| EIGR | 2 | LIMT HDV | interim data study at AASLD |
| GALT | 2b | NASH-CX | Clinical data in December |
| IRWD | 2 | IW-1973 | data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017. |
| KDMN | 2 | KD025 | Randomized, open-label clinical trial in idiopathic pulmonary fibrosis |
| KDMN | 2 | KD025 | Randomized, open-label clinical trial in idiopathic pulmonary fibrosis and full data to severe psoriasis |
| KURA | 2 | tipifarnib | Phase 2 trial of tipifarnib in HRAS mutant SCCHN second half 2017 |
| MDGL | 2 | MGL-3196 for NASH | Top-line results for the primary endpoint of the trial, the reduction of liver fat, assessed by MRI-PDFF at 12 weeks, are expected by year-end |
| MLNT | 2/3 | Taksta | exploratory trial data in refractory bone and joint infections. |
| MNOV | 2b | SPRINT-MS/NN 102 | phase 2b Trial of Ibudilast in progressive MS has been accepted for oral platform presentation at 7th Join ECTRIMS*ACTRIMS meeting October 25-28, 2017 in Paris, France |
| ONTX | 3 | INSPIRE | interim analysis anticipate in Q4 |
| RARX | 2 | RA101495 | Cohort B of Ra Pharma's Phase 2. The company remains on track to report additional data around year-end. |
| RVNC | 2 | RT002 | RT002 injectable in management of plantar fascitis |
| RVNC | 3 | SAKURA 1&2 | rt002 Injectable for the treatment of glabellar (frown) lines |
| SAGE | 2 | SAGE-217 | SAGE-217 in PPD and essential tumor 2H2017 |
| SGEN | 3 | ADCETRIS | Full data from ADCETRIS phase 3 ECHELON-1 trial |
| STML | 2 | SL-401 | In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Top line results in 2h17 |
| SYRS | 2 | SY-1425 | on track to present initial phase 2 clinical data |
| TGTX | 2 | TG-1101 | multiples sclerosis trial update |
| VKTX | 2 | VK5211 | Phase 2 hip fractured study full enrolled, data expected Q4 '17. From Aug 19 press released |
| Ticker | Phase | Drug | Notes |
|---|---|---|---|
| ABBV | 3 | SELECT-BEYOND | top-line data likely 3Q |
| ABUS | 2 | HBV | ARB1467 data |
| ABUS | 2 | ARB-1467 | top-line results from the three-month bi-weekly dosing expect to be announced in September |
| ALDX | 2A | ADX-102 | Clinical trial in Dry Eye Disease |
| ALNY | 2 | hempohillia | Fitusiran PII OLE dadta |
| ALNY | 3 | APOLLO | results for Patisiran in near term |
| ANAB | 2a | ANB020 | Multiple Top-Line Clinical data Readouts expected in Second half of 2017 |
| ANTH | 2 | BRIGHT | BRIGHT study of blisibimod in IgA |
| ARRY | 3 | BEACON CRC | data from the safety due at ESMO |
| AXON | 3 | Alzheimer's disease | Data to be out in September 2017 |
| AZRX | IIa | MS1819 | expect completion Phase IIa in 3Q |
| BLPH | 2a | PH-IPF | "results of this study in near futture" -Mr. Tenenbaum |
| FOLD | 3 | SD-101 | SD-101 for Epidermolysis Bullosa (EB), Top-line P3 late 3Q |
| GILD | 2 | GS-0976 | NASH data |
| GTXI | 2 | Enobosarm | top-line results in 3Q |
| INSM | 3 | ARIKAYCE | data out in September |
| KDMN | 2 | KD025 | Open-label, dose finding clinical trial in chronic graft-versus-host disease. Also Tesevatinib data |
| MDCO | 3 | Meropenem-Vaborbactam | TANGO 2 end of 3Q |
| MRNS | 2 | CDKL5 | Phase 2 trial evaluating children with CDKL5 disorder |
| MRTX | 2 | NSCLL | AMETHYST trial |
| NBRV | 3 | Infections | LEAP 1 data. |
| OTIC | 3 | AVERTS-1 | Phase 3 AVERTS-1 trial for OTIVDEX(tm) in September |
| RDHL | 2 | BEKINDA | IBS-D data in September |
| SAGE | 3 | Brexanolone in SRSE | top-line results from STATUS trial |
| STML | 2 | SL-401 | top-line results in 2h17 |
| VNDA | 2 | Tradipitant | study for treatment of chronic pruritus in patients with atopic dermatitis. |
| VSAR | 3 | Pediatric GHD | Top line from pediatric phase 3 Velocity trial around end of September |
| VSTM | 3 | Duvelisib | Phase 3 DUO top-line latter part of summer |
| ZGNX | 3 | ZX008 | Top-line results of first Phase 3 Clinical trial of ZX008 in Dravet Syndrome |
| ZYNE | 2 | FAB-C | top-line results from the FAB-C Fragile X study in September |
